Seattle, Washington’s ZymoGenetics will cut 161 employees and discontinue research on cancer treatments.
The firm will continue to market its only approved product, the blood-clotting compound Recothrom Thrombin, and will narrow its research focus to immunology.
ZymoGenetics said the terminated employees will get severance benefits.
ZymoGenetics is a biotechnology and pharmaceutical firm involved in the development of therapeutic proteins. The company was founded in 1981 by Earl W. Davie and Benjamin D. Hall of the University of Washington, and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia.
INTERESTED IN IMPROVING YOUR CAREER? CHECK OUT …
|
THE CAREER TRANSFORMATION SYSTEM TM SIGN UP NOW! |
Resources
Search Jobs
Post Your Resume to 65+ Job Sites
Resume Service
Leave a Reply
You must be logged in to post a comment.